Other Clinical Trial - Safety & Immunogenicity Study of the Venezuelan

Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine — VEE TC-83

Venezuelan Equine Encephalomyelitis Clinical Trial

Official title:
A Phase 2 Open-Label, Safety and Immunogenicity Study of a Single Dose of Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried, TC-83, NDBR-102, as Primary Immunization in Healthy Adults At Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT00582088` - Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83	Phase 2
	Not yet recruiting	`NCT03531242` - Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults	Phase 2

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT00582088 - Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83

Phase 2

Not yet recruiting

NCT03531242 - Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00582504
Study type	Interventional
Source	U.S. Army Medical Research and Development Command
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	September 2007
Completion date	June 2022

Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine — VEE TC-83

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms